Galderma presented new three-year Nemluvio® data at Fall Clinical 2026, showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older.

The dataset extends the clinical profile of Nemluvio® (nemolizumab), Galderma's interleukin-31 receptor antagonist, into long-term territory for a cohort that spans adolescents from age 12 through adults. The company presented the findings at the Fall Clinical Dermatology Conference 2026, one of the field's major practice-oriented meetings.

What do the three-year data show?

According to the announcement, patients maintained deep responses in two of the domains that matter most in atopic dermatitis management: visible skin lesions and itch. Itch relief is a clinically central endpoint in atopic dermatitis, because pruritus drives sleep disruption, quality-of-life impairment and treatment dissatisfaction in this population.

Galderma characterized the results as demonstrating both depth and durability of response across the three-year observation period in patients aged 12 and older. These are manufacturer-presented data; peer-reviewed publication details, including exact responder rates and statistical framing, had not been disclosed in the announcement itself.

Why does a three-year timeline matter?

Atopic dermatitis is a chronic, relapsing inflammatory disease, and payers and clinicians have repeatedly flagged the scarcity of long-term safety and efficacy evidence for newer biologics. Data out to three years in a cohort that includes adolescents give prescribers a longer view of sustained lesion clearance and itch control than the typical pivotal trial window provides.

For dermatologists weighing maintenance therapy decisions, durability signals help address a practical question: whether deep responses achieved in the first months of treatment hold up over years of continuous use.

What is Nemluvio's regulatory footing?

Nemluvio® is Galderma's branded formulation of nemolizumab, an IL-31 receptor antagonist targeting the itch pathway central to atopic dermatitis. The new presentation covers patients aged 12 and older, the age range reflected in the reported study population.

Dermatologists attending Fall Clinical 2026 will be watching for the full data tables — responder thresholds, discontinuation rates and safety events over the three-year period — as the results move from conference presentation toward publication.

Galderma's next step will be submitting the long-term dataset for peer review, which will determine how much of the durability signal translates into prescribing guidance and coverage decisions for adolescent and adult atopic dermatitis patients.